Neurocrine Biosciences INC Form 4 insider transactions

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Kevin Charles Gorman, a Director of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Kyle Gano, Chief Executive Officer and a Director of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

David W. Boyer, Chief Corp. Affairs Officer of Neurocrine Biosciences Inc, sold 826 shares of common stock on September 11, 2026 for $157.45 per share.

Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.

Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc, sold 2,311 shares of common stock on September 11, 2026 for $157.20 per share.

Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc, sold 2,154 shares of common stock on September 9, 2026 for $154.61 per share.

Stephen A Sherwin, a Director of Neurocrine Biosciences Inc, reported a transaction in 1,000 shares of common stock on September 2, 2026.

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc, reported a transaction in 2,409 shares of common stock on August 4, 2026.

Leslie Norwalk V, a Director of Neurocrine Biosciences Inc, sold 1,250 shares of common stock on July 28, 2026 for $182.01 per share.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences Inc, sold 4,367 shares of common stock on July 10, 2026 for $181.02 per share.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc, sold 10,000 shares of common stock on July 9, 2026 for $179.60 per share.

Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences, executed a series of transactions involving the purchase and sale of company common stock, primarily under a Rule 10b5-1 trading plan.

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt reported transactions involving the sale of company stock, executed under a pre-established Rule 10b5-1 trading plan.

Neurocrine Biosciences Director Stephen Sherwin exercised stock options and sold 25,000 shares under a 10b5-1 trading plan.

Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported a gift of 2,441 common stock shares effective June 5, 2026.

Neurocrine Biosciences Director Leslie Norwalk sold 1,250 shares of common stock via a pre-arranged 10b5-1 trading plan.

Chief Human Resources Officer Julie Cooke exercised stock options and sold shares under a Rule 10b5-1 trading plan.

Chief Medical Officer Sanjay Keswani acquired 3,212 shares of Neurocrine Biosciences common stock via RSU vesting.

Chief Scientific Officer Jude Onyia exercised options and sold 11,000 shares of Neurocrine Biosciences common stock.

Chief Regulatory Officer Ingrid Delaet exercised and sold 2,261 shares of Neurocrine Biosciences common stock via a 10b5-1 plan.

Chief Scientific Officer Jude Onyia exercised options and sold 11,000 shares of Neurocrine Biosciences common stock.

Director Kevin Gorman was granted 5,248 non-qualified stock options in Neurocrine Biosciences, Inc.

Neurocrine Biosciences Director Richard Pops was granted 2,567 restricted stock units vesting in May 2027.

Director Gary A. Lyons received a grant of restricted stock units and stock options from Neurocrine Biosciences.

Director Johanna Mercier was granted 2,567 restricted stock units by Neurocrine Biosciences, Inc. vesting in May 2027.